Bio-Path Holdings (BPTH-Q) Stock Price and News - The Globe and Mail

Add to Watchlist Create Alerts

Real-Time Last Update

Last Sale Cboe BZX Real-Time

Volume

Day Low2.61

Day High2.80

Open:2.77

Previous Close

52-Week High/Low

Volume

Average Volume

Price/Earnings (TTM)

Forward Annual Dividend & Yield

Market Capitalization, $M

5-Day Change

Realtime quote and/or trade prices are not sourced from all markets.

Bio-Path Holdings to Announce Second Quarter 2022 Financial Results on August 16, 2022

Bio-Path Holdings Reports First Quarter 2022 Financial Results

Bio-Path Holdings to Announce First Quarter 2022 Financial Results on May 17, 2022

Bio-Path Holdings Presents BP1003 Data at 2022 American Association for Cancer Research Annual Meeting

Bio-Path Holdings Reports Full Year 2021 Financial Results

Bio-Path Holdings to Present at the 2022 American Association for Cancer Research Annual Meeting

Bio-Path Holdings to Announce Full Year 2021 Financial Results on March 11, 2022

Bio-Path Holdings to Present at H.C. Wainwright BioConnect 2022 Virtual Conference

January 5, 2022

Bio-Path Holdings Presents Data from Ongoing Phase 2 Study of Prexigebersen at 2021 American Society of Hematology Annual Meeting

December 13, 2021

Bio-Path Holdings Reports Third Quarter 2021 Financial Results

November 12, 2021

Bio-Path Holdings to Announce Third Quarter 2021 Financial Results on November 12, 2021

November 5, 2021

Bio-Path Holdings to Present Clinical Data at the 63rd Annual American Society of Hematology Annual Meeting

November 4, 2021

Bio-Path Holdings Announces Clearance of Investigational New Drug Application for BP1002 in Refractory/Relapsed Acute Myeloid Leukemia Patients

August 24, 2021

Bio-Path Holdings Reports Second Quarter 2021 Financial Results

August 13, 2021

Bio-Path Holdings to Announce Second Quarter 2021 Financial Results on August 13, 2021

Bio-Path Granted Key Mechanism of Action U.S. Patent for BP1003

Bio-Path Holdings Reports First Quarter 2021 Financial Results

Bio-Path Holdings to Announce First Quarter 2021 Financial Results on May 14, 2021

Bio-Path Announces Publication in Biomedicines

Bio-Path Holdings Presents BP1002 Data at 2021 American Association for Cancer Research Annual Meeting

Bio-Path Holdings Announces Successful Completion of Safety Cohort of Triple Combination of Prexigebersen, Decitabine and Venetoclax in Stage 2 of Phase 2 Clinical Trial in Acute Myeloid Leukemia

Bio-Path Holdings to Present at the 2021 American Association for Cancer Research Annual Meeting

Bio-Path Holdings Reports Full Year 2020 Financial Results

Bio-Path Holdings to Announce Full Year 2020 Financial Results on March 10, 2021

Bio-Path Holdings, Inc. Announces Closing of $13.0 Million Public Offering of Common Stock

February 18, 2021

Bio-Path Holdings, Inc. Announces Pricing of $13.0 Million Public Offering of Common Stock

February 16, 2021

Bio-Path Holdings, Inc. Announces Proposed Public Offering of Common Stock

February 13, 2021

Bio-Path Receives Third U.S. Patent Grant Related to Manufacture of Platform Technology

February 10, 2021

Bio-Path Holdings Announces First Patient Dosed in Phase 1 Clinical Trial of BP1002

November 19, 2020

Bio-Path Holdings Reports Third Quarter 2020 Financial Results

November 13, 2020

Bio-Path Holdings to Announce Third Quarter 2020 Financial Results on November 13, 2020

November 6, 2020

Bio-Path Receives Notice of Allowance for Strategic Patent for Prexigebersen in Combination with Front Line Cytidine Analogues or Bcr-Abl Tyrosine Kinase Inhibitors in a Variety of Cancers

October 22, 2020

Profile

BIO-PATH is developing leading-edge, patented, liposomal drug delivery systems, with two clinical cancer drug candidates ready for the clinic and a third siRNA cancer drug undergoing final pre-clinical development. Bio-Path's drug delivery technology distributes nucleic acid drugs systemically, throughout the human body, via simple intravenous infusion. The delivery technology can be applied both to double stranded and single stranded nucleic acid compounds with the potential to revolutionize the treatment of cancer and other diseases where drugable targets of disease are well characterized.